18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: The Ottawa-FIVE substudy of the PARR 2 trial

Journal of Nuclear Medicine

Volumn 51, Issue 4, 2010, Pages 567-574

  Abraham, Arun ^a   Nichol, Graham ^b   Williams, Kathryn A ^a   Guo, Ann ^a   DeKemp, Robert A ^a   Garrard, Linda ^a   Davies, Ross A ^a   Duchesne, Lloyd ^a   Haddad, Haissam ^a   Chow, Benjamin ^a   DaSilva, Jean ^a   Beanlands, Rob S B ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cardiology (clinical); Fluorodeoxyglucose; LV dysfunction; PET; Viability

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; HEALTH CARE MANAGEMENT; HEART DEATH; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; POST HOC ANALYSIS; PRIORITY JOURNAL; REVASCULARIZATION; CANADA; COOPERATION; HEART; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; PROFESSIONAL COMPETENCE; RANDOMIZED CONTROLLED TRIAL; SCINTISCANNING; SURVIVAL; TISSUE SURVIVAL;

CANADA; COOPERATIVE BEHAVIOR; CORONARY ARTERY DISEASE; FEMALE; FLUORODEOXYGLUCOSE F18; HEART; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; POSITRON-EMISSION TOMOGRAPHY; PROFESSIONAL COMPETENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TISSUE SURVIVAL; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77950961221     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.065938     Document Type: Article

References (30)

1. Jones RH. Is it time for a randomized trial of surgical treatment of ischemic heart failure? J Am Coll Cardiol. 2001;37:1210-1213.
2. Kron IL, Flanagan TL, Blackbourne LH, Schroeder RA, Nolan SP. Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy. Ann Surg. 1989;210:348-352.
3. Tjan TD, Kondruweit M, Scheld HH, et al. The bad ventricle: revascularization versus transplantation. Thorac Cardiovasc Surg. 2000;48:9-14.
4. Schinkel AFL, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32:375-410.
5. Machac J, Bacharach SL, Bateman TM, et al. Positron emission tomography myocardial perfusion and glucose metabolism imaging. J Nucl Cardiol. 2006; 13:e121-e151.
6. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151-1158.
7. Di Carli MF, Davidson M, Little R, et al. Value of metabolic imaging with positron 18 emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994;73:527-533.
8. Di Carli MF, Maddahi J, Rokhsar S, et al. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg. 1998;116:997-1004. (Pubitemid 28553544)
9. Lee KS, Marwick TH, Cook SA, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction: relative efficacy of medical therapy and revascularization. Circulation. 1994;90:2687-2694.
10. Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol. 1997;30:1693-1700.
11. Desideri A, Cortigiani L, Christen AI, et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol. 2005;46:1264-1269.
12. vom Dahl J, Altehoefer C, Sheehan FH, et al. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J Nucl Med. 1997;38:742-748.
13. Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 319 year mortality with and without revascularization. J Am Coll Cardiol. 1993;22:984-997. (Pubitemid 23285746)
14. 18F-FDG PET. J Nucl Med. 2001;42:1166-1173.
15. Beanlands RS, Nichol G, Huszti E, et al. F-18fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002-2012.
16. Gould KL. Not all randomized trials are equal. J Am Coll Cardiol. 2007; 50:2013-2015.
17. Beanlands R, Nichol G, Ruddy TD, et al. Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods. Control Clin Trials. 2003;24:776-794.
18. Beanlands RS, Ruddy TD, deKemp RA, et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol. 2002;40:1735-1743.
19. 18F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. J Nucl Med. 2001;42:1730-1736.
20. Altman DG, Bland JM. Interaction revisited: the difference between two estimates [letter]. BMJ. 2003;326:219.
21. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:e1-e82.
22. Douglas PS. Improving imaging: our professional imperative. J Am Coll Cardiol. 2006;48:2152-2155.
23. Beanlands RS, deKemp RA, Smith S, Johansen H, Ruddy TD. F-18-fluorodeoxyglucose PET imaging alters clinical decision making in patients with impaired ventricular function. Am J Cardiol. 1997;79:1092-1095.
24. Canto JG, Every NR, Magid DJ, et al. The Volume of Primary Angioplasty Procedures and Survival After Acute Myocardial Infarction. National Registry of Myocardial Infarction 2 Investigators. N Engl J Med. 2000;342:1573-1580.
25. Garcia MJ, Lessick J, Hoffmann MHK, for the CSI. Accuracy of 16-row multidetector computed tomography for the assessment of coronary artery stenosis. JAMA. 2006;296:403-411.
26. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349:2117-2127.
27. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21:2917-2930.
28. Schulz KF, Grimes DA. Multiplicity in randomized trials II: subgroup and interim analyses. Lancet. 2005;365:1657-1661.
29. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine: reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189-2194.
30. D'Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of hibernating myocardium: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging. 2009;2:1060-1068.